Send to

Choose Destination
Br J Psychiatry Suppl. 2004 Apr;47:S94-101.

Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications.

Author information

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA.

Erratum in

  • Br J Psychiatry Suppl. 2005 May;186:449.



In this retrospective analysis, we assessed the short-term risk of treatment-emergent diabetes (TED) among patients with schizophrenia during clinical trials of antipsychotic medications.


From a non-diabetic cohort of patients with schizophrenia (n=5013), the relationship between baseline non-fasting glucose measurement, presence at baseline of risk factors for diabetes, weight gain and therapy assignment on the risk of treatment-emergent diabetes were assessed.


At the baseline assessment, about a third of patients identified with TED during treatment had non-fasting glucose levels over 7.8 mmol/l and two-thirds had multiple diabetes risk factors. Both baseline non-fasting glucose level and the presence of multiple pre-existing diabetes risk factors appeared to have a major impact on the risk of developing diabetes.


Overall, risk factors for diabetes in patients with schizophrenia overlap those in the general population. The results also suggest that many patients identified with TED might have had pre-existing glycaemic abnormalities or a high baseline burden of diabetes risk factors.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center